Precision for Medicine Acquires ACT Oncology         

Julia A. Amo

Chief Operating Officer

Julia Amo possesses over 25 years of leadership experience in the pharmaceutical, CRO and healthcare industries. In her role as Chief Operating Officer, Julia is responsible for leading strategic planning and execution, building operations infrastructure, and overseeing the Business Operations, Business Development and Marketing functions within ACT Oncology.

Julia possesses extensive multi-disciplinary drug development experience at the project, compound and portfolio levels. She has held a number of leadership positions within the Pharmaceutical and CRO industries - most recently at PharmaNet/i3 as Vice President of Corporate Strategic Initiatives. In this position, and as a member of the Executive Team, she led strategic planning and implementation and played an integral role in the principal design and integration of the PharmaNet and i3 organizations. Prior to PharmaNet/i3, Julia was Vice President of Business Operations and Project Management at Valeant Pharmaceuticals, where she managed Valeant’s R&D drug development portfolio and also led a number of corporate strategic initiatives, including two NDA submissions. Throughout Julia’s career, she has headed several restructuring and turnaround initiatives at departmental and corporate levels.

Julia earned an MBA from St. Joseph University Haub School of Business, and a Bachelor’s of Science Degree in Nursing from Niagara University. She holds a PMP certification from the Project Management Institute and her certification in Executive and Leadership Coaching from Columbia University. Julia is also a founding member of the Board of Directors of the Pharmaceutical Metrics Consortium (MCC), a leading edge organization designed to increase the efficiency of clinical trial research processes.


We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at to see how we’re delivering the next generation of CRO services for oncology innovators.